SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Mimedx Group, Inc. – ‘10-K/A’ for 12/31/15 – ‘EX-23.1’

On:  Wednesday, 2/22/17, at 9:12am ET   ·   For:  12/31/15   ·   Accession #:  1376339-17-18   ·   File #:  1-35887

Previous ‘10-K’:  ‘10-K’ on 2/29/16 for 12/31/15   ·   Next:  ‘10-K’ on 3/1/17 for 12/31/16   ·   Latest:  ‘10-K’ on 2/28/24 for 12/31/23

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 2/22/17  Mimedx Group, Inc.                10-K/A     12/31/15   83:6.7M

Amendment to Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K/A      Amendment to Annual Report                          HTML    421K 
 2: EX-23.1     Consent of Experts or Counsel                       HTML     23K 
 3: EX-31.1     Certification -- §302 - SOA'02                      HTML     29K 
 4: EX-31.2     Certification -- §302 - SOA'02                      HTML     29K 
 5: EX-32.1     Certification -- §906 - SOA'02                      HTML     24K 
 6: EX-32.2     Certification -- §906 - SOA'02                      HTML     24K 
13: R1          Document and Entity Information                     HTML     50K 
14: R2          Consolidated Balance Sheets                         HTML     99K 
15: R3          Consolidated Balance Sheets (Parenthetical)         HTML     44K 
16: R4          Consolidated Statements of Operations               HTML     74K 
17: R5          Consolidated Statements of Stockholders' Equity     HTML    105K 
18: R6          Consolidated Statements of Stockholders' Equity     HTML     26K 
                (Parenthetical)                                                  
19: R7          Consolidated Statements of Cash Flows               HTML    107K 
20: R8          Nature of Business                                  HTML     27K 
21: R9          Significant Accounting Policies                     HTML     65K 
22: R10         Liquidity and Capital Resources                     HTML     27K 
23: R11         Cash Equivalents and Short Term Investments         HTML     25K 
24: R12         Inventories                                         HTML     36K 
25: R13         Investments                                         HTML     24K 
26: R14         Property and Equipment                              HTML     40K 
27: R15         Intangible Assets and Royalty Agreement             HTML     62K 
28: R16         Long-Term Debt                                      HTML     32K 
29: R17         Net Income (loss) Per Share                         HTML     49K 
30: R18         Common Stock Placements                             HTML     31K 
31: R19         Equity                                              HTML    137K 
32: R20         Income Taxes                                        HTML     91K 
33: R21         Supplemental Disclosure of Cash Flow and Non-Cash   HTML     53K 
                Investing and Financing Activities                               
34: R22         401k Plan                                           HTML     28K 
35: R23         Commitments and Contingencies                       HTML     62K 
36: R24         Quarterly Financial Data (Unaudited)                HTML     92K 
37: R25         Subsequent Events                                   HTML     26K 
38: R26         Schedule II - Valuation and Qualifying Accounts     HTML     70K 
39: R27         Significant Accounting Policies (Policies)          HTML    128K 
40: R28         Inventories (Tables)                                HTML     35K 
41: R29         Property and Equipment (Tables)                     HTML     37K 
42: R30         Intangible Assets and Royalty Agreement (Tables)    HTML     62K 
43: R31         Net Income (loss) Per Share (Tables)                HTML     50K 
44: R32         Equity (Tables)                                     HTML    136K 
45: R33         Income Taxes (Tables)                               HTML     85K 
46: R34         Supplemental Disclosure of Cash Flow and Non-Cash   HTML     52K 
                Investing and Financing Activities (Tables)                      
47: R35         Commitments and Contingencies (Tables)              HTML     30K 
48: R36         Quarterly Financial Data (Unaudited) (Tables)       HTML     90K 
49: R37         Nature of Business (Details)                        HTML     24K 
50: R38         Significant Accounting Policies (Details)           HTML     64K 
51: R39         Liquidity and Capital Resources (Details)           HTML     45K 
52: R40         Cash Equivalents and Short Term Investments         HTML     32K 
                (Details)                                                        
53: R41         Inventories (Details)                               HTML     36K 
54: R42         Investments (Details)                               HTML     26K 
55: R43         Property and Equipment (Details)                    HTML     50K 
56: R44         Intangible Assets and Royalty Agreement Intangible  HTML     87K 
                Asssets Activity Summary (Details)                               
57: R45         Intangible Assets and Royalty Agreement Expected    HTML     38K 
                Future Amortization of Intangible Assets (Details)               
58: R46         Long-Term Debt (Details)                            HTML     78K 
59: R47         Net Income (loss) Per Share Computation of Basic    HTML     49K 
                and Dilutive Net Loss per Share (Details)                        
60: R48         Net Income (loss) Per Share Summary of              HTML     34K 
                Antidilutive Securities (Details)                                
61: R49         Common Stock Placements (Details)                   HTML     32K 
62: R50         Equity Narrative (Details)                          HTML     82K 
63: R51         Equity Activity of Stock Options (Details)          HTML     77K 
64: R52         Equity Exercise Price Ranges (Details)              HTML     74K 
65: R53         Equity Summary of Unvested Stock Options (Details)  HTML     42K 
66: R54         Equity Assumptions (Details)                        HTML     39K 
67: R55         Equity Summary of Restricted Stock Awards           HTML     47K 
                (Details)                                                        
68: R56         Equity Recognized Stock-Based Compensation          HTML     32K 
                (Details)                                                        
69: R57         Income Taxes Deferred Tax Assets and Liabilities    HTML     50K 
                (Details)                                                        
70: R58         Income Taxes Reconciliation of the Federal          HTML     46K 
                Statutory Income Tax (Details)                                   
71: R59         Income Taxes Schedule of current and deferred       HTML     48K 
                income tax expense (Benefit) (Details)                           
72: R60         Income Taxes Reconciliation of unrecognized tax     HTML     27K 
                benefits (Details)                                               
73: R61         Income Taxes Narrative (Details)                    HTML     49K 
74: R62         Supplemental Disclosure of Cash Flow and Non-Cash   HTML     60K 
                Investing and Financing Activities (Details)                     
75: R63         401k Plan (Details)                                 HTML     34K 
76: R64         Commitments and Contingencies Estimated Annual      HTML     33K 
                Lease, Royalty, and Employment Agreement Expenses                
                (Details)                                                        
77: R65         Commitments and Contingencies Narrative (Details)   HTML     64K 
78: R66         Quarterly Financial Data (Unaudited) (Details)      HTML     45K 
79: R67         Subsequent Events (Details)                         HTML     41K 
80: R68         Schedule II - Valuation and Qualifying Accounts     HTML     39K 
                (Details)                                                        
82: XML         IDEA XML File -- Filing Summary                      XML    141K 
81: EXCEL       IDEA Workbook of Financial Reports                  XLSX     92K 
 7: EX-101.INS  XBRL Instance -- mdxg-20151231                       XML   1.89M 
 9: EX-101.CAL  XBRL Calculations -- mdxg-20151231_cal               XML    211K 
10: EX-101.DEF  XBRL Definitions -- mdxg-20151231_def                XML    556K 
11: EX-101.LAB  XBRL Labels -- mdxg-20151231_lab                     XML   1.70M 
12: EX-101.PRE  XBRL Presentations -- mdxg-20151231_pre              XML    965K 
 8: EX-101.SCH  XBRL Schema -- mdxg-20151231                         XSD    148K 
83: ZIP         XBRL Zipped Folder -- 0001376339-17-000018-xbrl      Zip    225K 


‘EX-23.1’   —   Consent of Experts or Counsel


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 <!   C:   C: 
  Exhibit  


Consent of Independent Registered Public Accounting Firm
We hereby consent to the incorporation by reference in the Registration Statements (Form S-8 Nos. 333-153255, 333-183991, 333-189784, 333-199841, and 333-211900 and Form S-3 No. 333-189785) of our reports dated February 29, 2016, included in this Annual Report on Form 10-K/A of MiMedx Group, Inc. and Subsidiaries (the Company) relating to the consolidated balance sheets of the Company as of December 31, 2015 and 2014, and the related consolidated statements of operations, stockholders’ equity, and cash flows and the related consolidated financial statement schedule for each of the three years in the period ended December 31, 2015, and the effectiveness of internal control over financial reporting for the Company as of December 31, 2015.

/s/ Cherry Bekaert LLP
Atlanta, Georgia
February 22, 2017





Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K/A’ Filing    Date    Other Filings
Filed on:2/22/174
2/29/1610-K,  4
For Period end:12/31/1510-K,  5
12/31/1410-K,  5,  8-K,  ARS
 List all Filings 
Top
Filing Submission 0001376339-17-000018   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., May 2, 2:32:19.1am ET